Paratek Pharmaceuticals Inc (PRTK) Earns “Outperform” Rating from Robert W. Baird

Robert W. Baird restated their outperform rating on shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) in a research report sent to investors on Tuesday. The firm currently has a $40.00 price target on the specialty pharmaceutical company’s stock.

PRTK has been the subject of a number of other reports. BTIG Research started coverage on shares of Paratek Pharmaceuticals in a report on Thursday, December 22nd. They issued a buy rating and a $47.00 target price for the company. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, February 15th. Cantor Fitzgerald set a $28.00 target price on shares of Paratek Pharmaceuticals and gave the company a buy rating in a report on Tuesday, December 13th. Guggenheim reaffirmed a buy rating on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Finally, Wedbush reaffirmed an outperform rating and issued a $30.00 target price on shares of Paratek Pharmaceuticals in a report on Monday, April 3rd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $36.78.

Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 1.736% during mid-day trading on Tuesday, reaching $21.975. The company’s stock had a trading volume of 816,312 shares. The firm’s market capitalization is $533.68 million. Paratek Pharmaceuticals has a 52 week low of $9.80 and a 52 week high of $25.00. The company’s 50-day moving average price is $18.64 and its 200 day moving average price is $15.06.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Thursday, March 2nd. The specialty pharmaceutical company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.17. The business earned $0.03 million during the quarter.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/04/21/paratek-pharmaceuticals-prtk-outperform-rating-reiterated-at-robert-w-baird-updated.html.

In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 3,405 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $51,381.45. Following the transaction, the chief financial officer now directly owns 58,983 shares in the company, valued at $890,053.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Evan Loh sold 3,106 shares of the company’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $15.09, for a total transaction of $46,869.54. Following the transaction, the chief operating officer now owns 102,873 shares in the company, valued at $1,552,353.57. The disclosure for this sale can be found here. Insiders have sold 11,511 shares of company stock worth $173,701 over the last 90 days. 2.00% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Paratek Pharmaceuticals by 196.5% in the third quarter. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company’s stock valued at $104,000 after buying an additional 5,305 shares during the last quarter. Ardsley Advisory Partners acquired a new stake in Paratek Pharmaceuticals during the third quarter valued at approximately $130,000. Dynamic Technology Lab Private Ltd acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $158,000. Ellington Management Group LLC acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $179,000. Finally, Baird Financial Group Inc. acquired a new stake in Paratek Pharmaceuticals during the fourth quarter valued at approximately $216,000. Institutional investors own 76.06% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply